Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 17.5% on Friday . The company traded as high as C$0.24 and last traded at C$0.24. 865,576 shares traded hands during mid-day trading, an increase of 50% from the average session volume of 576,068 shares. The stock had previously closed at C$0.20.
Hemostemix Trading Up 20.0 %
The business has a fifty day moving average price of C$0.09 and a two-hundred day moving average price of C$0.08. The company has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Differences Between Momentum Investing and Long Term Investing
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- What is a Special Dividend?
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- 3 Dividend Kings To Consider
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
